Theravance begins a new chapter on 15 May when it splits into two companies known as Theravance Royalty Management and Theravance Biopharma – the former charged with collecting cash from the sale of respiratory medicines partnered with GlaxoSmithKline and the latter focused on research and development.
Theravance begins a new chapter on 15 May when it splits into two companies known as Theravance Royalty Management and Theravance Biopharma – the former charged with collecting cash from the sale of respiratory medicines partnered with GlaxoSmithKline and the latter focused on research and development.
CEO Rick Winningham is looking forward to the end of Theravance's separation process, which the South San Francisco-based company kicked...
Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.
The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.
The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.
